| Id |
Subject |
Object |
Predicate |
Lexical cue |
| TextSentencer_T1 |
0-220 |
Sentence |
denotes |
Hypogammaglobulinemia with a selective delayed recovery in memory B cells and an impaired isotype expression after rituximab administration as an adjuvant to autologous stem cell transplantation for non-Hodgkin lymphoma. |
| TextSentencer_T2 |
221-232 |
Sentence |
denotes |
OBJECTIVES: |
| TextSentencer_T3 |
233-399 |
Sentence |
denotes |
Some studies have indicated patients who received rituximab as adjuvant to stem cell transplantation had an increased risk of developing severe hypogammaglobulinemia. |
| TextSentencer_T4 |
400-562 |
Sentence |
denotes |
The mechanism of this hypogammaglobulinemia is unknown, although investigators have hypothesized a further delay in the B-cell recovery as one potential etiology. |
| TextSentencer_T5 |
563-646 |
Sentence |
denotes |
The aim of this study is to clarify the mechanism(s) of this hypogammaglobulinemia. |
| TextSentencer_T6 |
647-655 |
Sentence |
denotes |
METHODS: |
| TextSentencer_T7 |
656-785 |
Sentence |
denotes |
A total of 14 patients with high-risk CD20+ lymphoma underwent an autologous peripheral blood stem cell transplantation (APBSCT). |
| TextSentencer_T8 |
786-889 |
Sentence |
denotes |
After a hematological recovery, rituximab was given weekly for up to four doses as an adjuvant therapy. |
| TextSentencer_T9 |
890-898 |
Sentence |
denotes |
RESULTS: |
| TextSentencer_T10 |
899-1083 |
Sentence |
denotes |
After a median follow up of 33.5 months, we found six patients (group A) who had hypogammaglobulinemia, while the eight other patients (group B) had normal serum immunoglobulin levels. |
| TextSentencer_T11 |
1084-1176 |
Sentence |
denotes |
A phenotypical analysis revealed that group A patients had already achieved B-cell recovery. |
| TextSentencer_T12 |
1177-1387 |
Sentence |
denotes |
However, we found a severe delay in the recovery of CD27+ memory B cells, especially in the IgD-/CD27+ switched populations in group A, but CD27 negative naive B-cells reverted to a normal range in both groups. |
| TextSentencer_T13 |
1388-1597 |
Sentence |
denotes |
Consistent with this, reverse transcriptase-polymerase chain reaction studies with peripheral blood mononuclear cells revealed that most patients in group A lacked more than two classes of isotype transcripts. |
| TextSentencer_T14 |
1598-1610 |
Sentence |
denotes |
CONCLUSIONS: |
| TextSentencer_T15 |
1611-1864 |
Sentence |
denotes |
Abnormal repertoires and impaired isotype expression are seen in patients with common variable immunodeficiency, these data suggested that rituximab after APBSCT can affect not only the B-cell quantities, but also the recovery of the B-cell repertoires. |
| T1 |
0-220 |
Sentence |
denotes |
Hypogammaglobulinemia with a selective delayed recovery in memory B cells and an impaired isotype expression after rituximab administration as an adjuvant to autologous stem cell transplantation for non-Hodgkin lymphoma. |
| T2 |
221-232 |
Sentence |
denotes |
OBJECTIVES: |
| T3 |
233-399 |
Sentence |
denotes |
Some studies have indicated patients who received rituximab as adjuvant to stem cell transplantation had an increased risk of developing severe hypogammaglobulinemia. |
| T4 |
400-562 |
Sentence |
denotes |
The mechanism of this hypogammaglobulinemia is unknown, although investigators have hypothesized a further delay in the B-cell recovery as one potential etiology. |
| T5 |
563-646 |
Sentence |
denotes |
The aim of this study is to clarify the mechanism(s) of this hypogammaglobulinemia. |
| T6 |
647-655 |
Sentence |
denotes |
METHODS: |
| T7 |
656-785 |
Sentence |
denotes |
A total of 14 patients with high-risk CD20+ lymphoma underwent an autologous peripheral blood stem cell transplantation (APBSCT). |
| T8 |
786-889 |
Sentence |
denotes |
After a hematological recovery, rituximab was given weekly for up to four doses as an adjuvant therapy. |
| T9 |
890-898 |
Sentence |
denotes |
RESULTS: |
| T10 |
899-1083 |
Sentence |
denotes |
After a median follow up of 33.5 months, we found six patients (group A) who had hypogammaglobulinemia, while the eight other patients (group B) had normal serum immunoglobulin levels. |
| T11 |
1084-1176 |
Sentence |
denotes |
A phenotypical analysis revealed that group A patients had already achieved B-cell recovery. |
| T12 |
1177-1387 |
Sentence |
denotes |
However, we found a severe delay in the recovery of CD27+ memory B cells, especially in the IgD-/CD27+ switched populations in group A, but CD27 negative naive B-cells reverted to a normal range in both groups. |
| T13 |
1388-1597 |
Sentence |
denotes |
Consistent with this, reverse transcriptase-polymerase chain reaction studies with peripheral blood mononuclear cells revealed that most patients in group A lacked more than two classes of isotype transcripts. |
| T14 |
1598-1610 |
Sentence |
denotes |
CONCLUSIONS: |
| T15 |
1611-1864 |
Sentence |
denotes |
Abnormal repertoires and impaired isotype expression are seen in patients with common variable immunodeficiency, these data suggested that rituximab after APBSCT can affect not only the B-cell quantities, but also the recovery of the B-cell repertoires. |